Anti cd19 apc clone hib19

Manufactured by BD

Sourced in Germany

Anti-CD19 APC (clone HIB19) is a fluorescently labeled antibody that binds to the CD19 surface antigen. CD19 is expressed on B cells and is commonly used as a marker for the identification and enumeration of B cell populations in flow cytometry applications.

Automatically generated - may contain errors

Lab products found in correlation

Anti cd3 v450 clone ucht1, by BD (2 mentions) Anti cd4 apc h7 clone rpa t4, by BD (2 mentions) Anti cd8 pacific orange clone rpa t8, by BioLegend (2 mentions) Anti cd25 pe cy7 clone m a251, by BD (2 mentions) Anti cd127 pe cy5 clone ebiordr5, by Thermo Fisher Scientific (2 mentions) Anti cd56 pe clone b159, by BD (2 mentions) Facscanto 2, by BD (2 mentions) Facsdiva software, by BD (2 mentions) Fortessa, by BD (1 mentions)

Close spelling variants of this product

CD19-APC (clone HIB19; Anti-CD19 APC (HIB19; CD19-APC (HIB19, CD19 (clone HIB19) Anti-CD19 (HIB19, CD19 (HIB19) Anti-CD19-APC CD19-APC Anti-CD19

3 protocols using anti cd19 apc clone hib19

Comprehensive Immune Cell Profiling

Check if the same lab product or an alternative is used in the 5 most similar protocols

CD4⁺ T cells were defined as CD3+CD4⁺; CD8⁺ T cells were defined as CD3⁺CD8⁺; CD8⁺ naïve cells were defined as CD8⁺CD45RO-CD62L⁺; CD4 Tregs were defined as CD3⁺CD4⁺CD25^med-highCD127^low; CD4 conventional T cells (Tcons) were defined as CD3⁺CD4⁺CD25^low-negCD127^med-high; natural killer (NK) cells as CD56⁺CD3⁻; and B cells as CD19⁺. Aliquots of anti-coagulated whole blood (ethylenediaminetetraacetic acid [EDTA]) were incubated with fluorophore-conjugated monoclonal antibodies: anti-CD3 V450 (clone UCHT1, BD Biosciences), anti-CD4 APC-H7 (clone RPA-T4, BD Biosciences), anti-CD8 Pacific-Orange (clone RPA-T8, Biolegend), anti-CD25 PE-Cy7 (clone M-A251, BD Biosciences), anti-CD127 PE-Cy5 (clone eBioRDR5, eBioscience) for T-cell subsets; anti-CD56 PE (clone B159, BD Biosciences), anti-CD3 V450 (clone UCHT1, BD Biosciences) for NK/NKT cells, and anti-CD19 APC (clone HIB19, BD Biosciences) for B cells. RBC lysis with BD Pharm Lyse was performed either prior to or following incubation with conjugated antibodies. Flow cytometry analysis utilized FACSCanto II (BD Bioscience) or the Fortessa (BD Bioscience) and FACSDiva software (BD Bioscience). There was a change in the use of flow cytometry machines over the course of the study. Both flow cytometers were validated and results were comparable.

Koreth J., Kim H.T., Lange P.B., Poryanda S.J., Reynolds C.G., Rai S.C., Armand P., Cutler C.S., Ho V.T., Glotzbecker B., Yusuf R., Nikiforow S., Chen Y.B., Dey B., McMasters M., Ritz J., Blazar B.R., Soiffer R.J., Antin J.H, & Alyea EP I.I.I. (2018). Bortezomib-based immunosuppression after reduced-intensity conditioning hematopoietic stem cell transplantation: randomized phase II results. Haematologica, 103(3), 522-530.

+ Open protocol

+ Expand

Comprehensive Immune Cell Profiling

Check if the same lab product or an alternative is used in the 5 most similar protocols

Immune reconstitution assays: CD4+ T cells were defined as CD3+CD4+; CD4+ naïve cells were defined as CD4+, CD45RO⁻; CD4+ memory cells were defined as CD4+CD45RO+; CD8+ T cells were defined as CD3+CD8+; CD8+ naïve cells were defined as CD8+CD45RO⁻CD62L+; CD8+ memory cells were defined as CD8+CD45RO+; CD8+ terminal effector cells were defined as CD8+CD45RO⁻CD62L⁻; CD4 regulatory T cells (Treg) were defined as CD3+CD4+CD25^med-highCD127^low; NK cells as CD56+CD3⁻; and B cells as CD19+. Fifty μl whole blood (15% EDTA) in 5 ml polystyrene round-bottom reaction tubes was incubated with fluorophore-conjugated monoclonal antibodies: anti-CD3 V450 (clone UCHT1, BD Biosciences), anti-CD4 APC-H7 (clone RPA-T4, BD Biosciences), anti-CD8 Pacific-Orange (clone RPA-T8, Biolegend), anti-CD25 PE-Cy7 (clone M-A251, BD Biosciences), anti-CD127 PE-Cy5 (clone eBioRDR5, eBioscience), anti-CD62L APC (clone DREG-56, BD Biosciences), CD45RO FITC (clone UCHL1, BD Biosciences) for T cell subsets; anti-CD56 PE (clone B159, BD Biosciences), anti-CD3 V450 (clone UCHT1, BD Biosciences) for NK/NKT cells; anti-CD19 APC (clone HIB19, BD Biosciences) for B cells. RBC lysis with 500 μl 1× BD Pharm Lyse followed. Immune reconstitution flow cytometry analysis utilized FACSCanto II (BD Bioscience) and FACSDiva software (BD Bioscience).

Koreth J., Kim H.T., Lange P.B., Bindra B., Reynolds C.G., Chammas M.J., Armand P., Cutler C.S., Ho V.T., Glotzbecker B., Nikiforow S., Ritz J., Blazar B.R., Soiffer R.J., Antin J.H, & Alyea EP I.I.I. (2015). A Bortezomib-based Regimen Offers Promising Survival and Graft-vs.-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 21(11), 1907-1913.

+ Open protocol

+ Expand

Lymphocyte Subset Analysis in RTX Treatment

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

Blood samples were drawn for evaluation of lymphocyte subsets on day 1 (60 min before the first infusion of RTX), on day 35 (1 week after the last infusion of RTX), and at weeks 24 after the last infusion of RTX. The B-cell surface antigen CD19⁺ was used as a marker for CD20⁺ because the CD20⁺ bound to RTX might interfere with the flow cytometric measurement [15 (link)]. The reference range (RR) in percentage for normal values of peripheral blood lymphocyte subsets were: 32–61% for circulating CD4⁺, 14–43% for circulating CD8⁺, and 5–20% for circulating CD19+ B cells [16 ] Peripheral blood mononuclear cells (PBMCs) were isolated and then stained [17 (link)] with monoclonal antibodies anti-CD4 FITC (clone REA623) (Milteny Biotec, Bergisch Gladbach, Germany), anti-CD8 PE (clone REA734), (Milteny Biotec, Bergisch Gladbach, Germany), anti-CD19 APC (clone HIB19) (BD Pharmingen, Milan, Italy), anti-CD20 PC5 (Clone B9E9) (Beckman Coulter, Indianapolis, Indiana USA). Immunophenotyping analysis was performed by multicolor flow cytometry, and cells were collected and analyzed with specific software, as previously reported [18 (link)].

Fortuna G., Calabria E., Aria M., Giudice A, & Mignogna M.D. (2021). Immunocytometric Analysis of Oral Pemphigus vulgaris Patients after Treatment with Rituximab as Adjuvant. Biomolecules, 11(11), 1634.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!